Showing results (531-540 of 556) with videos related to

Sort By:
Pageof 56
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|September 21, 2016
Pediatric Contact Dermatitis Registry Inaugural Case DataAlina Goldenberg, Nico Mousdicas, Nanette Silverberg, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Cutis|October 16, 2024
Top DEI Topics to Incorporate Into Dermatology Residency Training: An Electronic Delphi Consensus StudyValerie S Encarnación-Cortés, Ivan Rodriguez, Fatuma-Ayaan Rinderknecht, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Nature Biomedical Engineering|August 19, 2022
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein librariesJoel J Credle, Jonathan Gunn, Puwanat Sangkhapreecha, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2021
Neutralizing IFNL3 Autoantibodies in Severe COVID-19 Identified Using Molecular Indexing of Proteins by Self-AssemblyJoel J Credle, Jonathan Gunn, Puwanat Sangkhapreecha, et al.
Pageof 56